AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

OsteoProtect

Summary

Treatment of osteoporosis by inhibitors of sphingosine-1-phosphatase (S1P)-lyase.

Technology Benefits

Novel approach for treating reduced bone density/stability
Specific inhibitors identified
In vivo data available

Technology Application

Pharmacological therapy for osteoporotic fractures.

Detailed Technology Description

The inventors showed that S1P inhibited osteoclast function, but most importantly, stimulated osteoblasts to produce new bone. Thus, a sufficient S1P-concentration is fundamental for an osteoanabolic fine-tuning of the skelettal system. Furthermore they showed that high S1P counteracts obesity by reducing adipose tissue mass. According to the invention, in patients suffering from osteoporosis, bone formation may be facilitated (and obesity reduced) by administering inhibitors of the S1P-lyase (the key enzyme degrading S1P). An exemplary S1P-lyase inhibitor tested by the inventors is the compound 4deoxypyridoxin (DOP).

Type of Cooperation

Licensing

Application Date

07/03/2019 00:00:00

Application No.

WO2019EP55667 20190307

Classes

- international:
A61K31/417; A61K31/4415; A61K31/4439; A61P19/10; A61P3/06; A61P3/08
- cooperative:
A61K31/417 (EP); A61K31/4415 (EP); A61K31/4439 (EP); A61P19/10 (EP); A61P3/06 (EP); A61P3/08 (EP)

Others

Patent application

ID No.

4955

Country/Region

Germany

For more information, please click Here